Apheris revolutionises data privacy and AI in life sciences with federated computing
Their technology is being used by major pharmaceutical companies for AI-driven drug discovery, highlighting its credibility and potential impact.
Privacy and regulatory concerns have long hindered AI’s reliance on data, especially in sensitive fields like healthcare and life sciences. Apheris, a German startup co-founded by Robin Röhm, aims to solve this problem using federated computing—a decentralised approach that trains AI models without moving sensitive data.
The company’s approach is gaining traction among prominent clients like Roche and hospitals, and its technology is already being used in collaborative drug discovery efforts by pharmaceutical giants such as Johnson & Johnson and Sanofi. Apheris recently secured $8.25 million in Series A funding led by OTB Ventures and eCAPITAL, bringing its total funding to $20.8 million.
That follows a pivotal shift in 2023 to focus on the needs of data owners in the pharmaceutical and life sciences sectors. The pivot has paid off, quadrupling the company’s revenue since launching its redefined product, the Apheris Compute Gateway, which securely bridges local data and AI models.
With its new funding, Apheris plans to expand its team and refine its AI-driven solutions for complex challenges like protein prediction. By prioritising data security and privacy, the company aims to unlock previously inaccessible data for innovation, addressing a core barrier to AI’s transformative potential in life sciences.
About author
DW Team
The GIP Digital Watch Observatory team, consisting of over 30 digital policy experts from around the world, excels in the fields of research and analysis on digital policy issues. The team is backed by the creative prowess of Creative Lab Diplo and the technical expertise of the Diplo tech team.
